BMS-345541
BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM) . BMS-345541 binds at an allosteric site of IKK.
Product Specifications
CAS Number
[445430-58-0]
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
IKK
Type
Reference compound
Related Pathways
NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BMS-345541-free-base.html
Purity
99.71
Solubility
DMSO : 10 mg/mL (ultrasonic) |H2O : 2.5 mg/mL (ultrasonic)
Smiles
CC1=CN=C2C(NCCN)=NC3=CC=C(C)C=C3N21
Molecular Formula
C14H17N5
Molecular Weight
255.32
Precautions
H315, H319, H320
References & Citations
[1]Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278 (3), 1450-1456.|[2]Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12 (3 Pt 1), 950-960.|[3]MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52 (12), 508-511.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IKK-α; IKK-β
Citation 01
Aging (Albany NY) . 2021 Aug 10;13 (15) :19088-19107.|Am J Hematol. 2024 Jul;99 (7) :1326-1337.|Am J Physiol Endocrinol Metab. 2021 Apr 1;320 (4) :E732-E746.|Biochem Biophys Res Commun. 2023 Nov 5:680:127-134.|Biomed Pharmacother. 2020 Jul;127:110116.|bioRxiv. 2025 Aug 13:2025.08.11.669793.|bioRxiv. 2025 Oct 25.|Cancer Metab. 2024 Jul 8;12 (1) :20.|Cancer Sci. 2025 Nov 14.|EMBO Mol Med. 2025 Apr;17 (4) :645-678.|EMBO Mol Med. 2025 Nov 26.|Front Microbiol. 2021 Feb 2;12:607451.|Int Immunopharmacol. 2021 Dec;101 (Pt A) :108264.|Int J Biol Macromol. 2025 Dec;334 (Pt 1) :149021.|iScience. 2024 May 16.|J Dent Res. 2019 Jul;98 (8) :896-903.|J Pharmacol Sci. 2023 Dec;153 (4) :188-196.|J Vet Sci. 2023 Sep;24 (5) :e72.|J Virol. 2019 Nov 26;93 (24) :e01499-19.|Molecules. 2025 May 2;30 (9) :2025.|Nat Metab. 2023 Mar;5 (3) :481-494.|Photobiomodul Photomed Laser Surg. 2025 Jul 24.|PLoS Comput Biol. 2020 Jun 26;16 (6) :e1007901.|PLoS Pathog. 2025 Oct 24;21 (10) :e1013646.|Research Square Print. October 27th, 2022.|Sci Transl Med. 2021 Jan 27;13 (578) :eaba7308.|Cancer Cell. 2015 Mar 9;27 (3) :409-25. |Cell Res. 2019 Mar;29 (3) :193-205. |Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Harvard Medical School LINCS LIBRARY|J Mol Med. 2020 Oct;98 (10) :1479-1491.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MF-0135016-01 5 µg
Influenza A H2N2 (A/Guiyang/1/1957) Hemagglutinin/HA Protein (His)
Ask
View Details 
MF-0135016-02 10 µg
Influenza A H2N2 (A/Guiyang/1/1957) Hemagglutinin/HA Protein (His)
Ask
View Details MF-0135016-03 20 µg
Influenza A H2N2 (A/Guiyang/1/1957) Hemagglutinin/HA Protein (His)
Ask
View Details 
MF-0135016-04 50 µg
Influenza A H2N2 (A/Guiyang/1/1957) Hemagglutinin/HA Protein (His)
Ask
View Details MF-0135016-05 100 µg
Influenza A H2N2 (A/Guiyang/1/1957) Hemagglutinin/HA Protein (His)
Ask
View Details